Clinical implications of p53 mutations

被引:0
|
作者
R. R. Wallace-Brodeur
S. W. Lowe
机构
[1] Cold Spring Harbor Laboratory,
[2] 1 Bungtown Rd.,undefined
[3] P.O. Box 100,undefined
[4] Cold Spring Harbor (New York 11724,undefined
[5] USA),undefined
[6] Fax +1 516 367 8454,undefined
[7] e-mail: lowe@cshl.org,undefined
关键词
Key words. Apoptosis; chemotherapy; prognosis; tumor suppressor; cancer genetics; clinical outcome.;
D O I
暂无
中图分类号
学科分类号
摘要
The ultimate goal of basic cancer research is to provide a theoretical foundation for rational approaches to improve cancer therapy. Our extensive insight into the biology of the p53 tumour suppressor and the clinical behaviour of tumours harbouring p53 mutations indicates that information concerning p53 will be useful in diagnosis and prognosis, and may ultimately produce new therapeutic strategies. At the same time, efforts to understand the clinical implications of p53 mutations have revealed conceptual and technical limitations in translating basic biology to the clinic. The lessons learned from p53 may lay the groundwork for future efforts to synthesize cancer gene function, cancer genetics and cancer therapy.
引用
收藏
页码:64 / 75
页数:11
相关论文
共 50 条
  • [31] p53 mutations in ocular tumor
    Chen, PM
    Liu, JH
    Lin, SH
    Fan, S
    Hsieh, RK
    Kao, SC
    Chiou, TJ
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 688 - 688
  • [32] P53 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
    LUDWIG, L
    SCHULZ, AS
    JANSSEN, JWG
    GRUNEWALD, K
    BARTRAM, CR
    LEUKEMIA, 1992, 6 (12) : 1302 - 1304
  • [33] P53 MUTATIONS IN GASTRIC CARCINOMAS
    SERUCA, R
    DAVID, L
    HOLM, R
    NESLAND, JM
    FANGAN, BM
    CASTEDO, S
    SOBRINHOSIMOES, M
    BORRESEN, AL
    BRITISH JOURNAL OF CANCER, 1992, 65 (05) : 708 - 710
  • [34] p53 mutations in malignant gliomas
    Li, Y
    Millikan, RC
    Carozza, S
    Newman, B
    Liu, E
    Davis, R
    Miike, R
    Wrensch, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1998, 7 (04) : 303 - 308
  • [35] P53 mutations in solar keratoses
    Park, WS
    Lee, HK
    Lee, JY
    Yoo, NJ
    Kim, CS
    Kim, SH
    HUMAN PATHOLOGY, 1996, 27 (11) : 1180 - 1184
  • [36] p53: Functions, mutations and sarcomas
    Hung, J
    Anderson, R
    ACTA ORTHOPAEDICA SCANDINAVICA, 1997, 68 : 68 - 73
  • [37] P53 MUTATIONS IN LARYNX CANCER
    ZHANG, LF
    HEMMINKI, K
    SZYFTER, K
    SZYFTER, W
    SODERKVIST, P
    CARCINOGENESIS, 1994, 15 (12) : 2949 - 2951
  • [38] Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY
    Watanabe, J
    Nishiyama, H
    Okubo, K
    Takahashi, T
    Toda, Y
    Habuchi, T
    Kakehi, Y
    Tada, M
    Ogawa, O
    UROLOGY, 2004, 63 (05) : 989 - 993
  • [39] P53 MUTATIONS OCCUR IN CLINICAL, BUT NOT LATENT, HUMAN PROSTATE CARCINOMA
    KONISHI, N
    HIASA, Y
    HAYASHI, I
    MATSUDA, H
    TSUZUKI, T
    MING, T
    KITAHORI, Y
    SHIRAISHI, T
    YATANI, R
    SHIMAZAKI, J
    JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (01): : 57 - 63
  • [40] Clinical classification of families with germline mutations in the p53 gene and their management
    Eeles, R
    JOURNAL OF MEDICAL GENETICS, 2000, 37 : S21 - S21